Association Between Azithromycin Therapy and Duration of Bacterial Shedding Among Patients With Shiga Toxin-Producing Enteroaggregative Escherichia coli O104:H4

被引:111
作者
Nitschke, Martin [2 ]
Sayk, Friedhelm [2 ]
Haertel, Christoph [3 ]
Roseland, Rahel Tabea [1 ]
Hauswaldt, Susanne [1 ]
Steinhoff, Juergen [2 ]
Fellermann, Klaus [2 ]
Derad, Inge [2 ]
Wellhoener, Peter [2 ]
Buening, Juergen [2 ]
Tiemer, Bettina [5 ]
Katalinic, Alexander [6 ]
Rupp, Jan [1 ,4 ]
Lehnert, Hendrik [2 ]
Solbach, Werner [1 ]
Knobloch, Johannes K. -M. [1 ]
机构
[1] Univ Hosp Schleswig Holstein, Dept Med Microbiol & Hyg, D-23538 Lubeck, Germany
[2] Univ Hosp Schleswig Holstein, Dept Internal Med 1, D-23538 Lubeck, Germany
[3] Univ Hosp Schleswig Holstein, Dept Pediat, D-23538 Lubeck, Germany
[4] Univ Hosp Schleswig Holstein, Dept Internal Med Infect Dis 3, D-23538 Lubeck, Germany
[5] Lab Gemeinschaftspraxis Lubeck, Lubeck, Germany
[6] Med Univ Lubeck, Inst Clin Epidemiol, D-23538 Lubeck, Germany
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2012年 / 307卷 / 10期
关键词
HEMOLYTIC-UREMIC SYNDROME; ANTIBIOTIC-TREATMENT; TRAVELERS DIARRHEA; EPIDEMIOLOGY; OUTBREAK; RISK;
D O I
10.1001/jama.2012.264
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context An outbreak of Shiga toxin-producing enteroaggregative Escherichia coli (STEC O104:H4) infection with a high incidence of hemolytic uremic syndrome (HUS) occurred in Germany in May 2011. Antibiotic treatment of STEC infection is discouraged because it might increase the risk of HUS development. However, antibiotic therapy is widely used to treat enteroaggregative E coli infection. In the German outbreak, a substantial number of patients received prophylactic azithromycin treatment as part of a therapeutic regimen with the C5 antibody eculizumab. Objective To analyze the duration of bacterial shedding in patients with STEC infection who did and did not receive oral azithromycin therapy. Design, Setting, and Patients At a single center in Lubeck, Germany, 65 patients with STEC infection, including patients with HUS as well as STEC-infected outpatients without manifestation of HUS, were investigated between May 15 and July 26, 2011, and were monitored for a mean of 39.3 days after onset of clinical symptoms. Main Outcome Measure Carriage of STEC after azithromycin therapy. Results Twenty-two patients received oral azithromycin and 43 patients did not receive antibiotic treatment. Among antibiotic-treated patients, long-term STEC carriage (>28 days) was observed in 1 of 22 patients (4.5%; 95% CI, 0%-13.3%) compared with 35 of 43 patients (81.4%; 95% CI, 69.8%-93.0%) who were not treated with antibiotics (P<.001). All 22 patients receiving azithromycin treatment had at least 3 STEC-negative stool specimens after the completion of treatment, and no recurrence of STEC was observed in these patients. As proof of principle, 15 patients who initially were not treated with antibiotics and were long-term STEC carriers were treated with oral azithromycin given for 3 days and subsequently had negative stool specimens. Conclusion Treatment with azithromycin was associated with a lower frequency of long-term STEC O104: H4 carriage. JAMA. 2012;307(10):1046-1052 www.jama.com
引用
收藏
页码:1046 / 1052
页数:7
相关论文
共 26 条
[1]   Characterisation of the Escherichia coli strain associated with an outbreak of haemolytic uraemic syndrome in Germany, 2011: a microbiological study [J].
Bielaszewska, Martina ;
Mellmann, Alexander ;
Zhang, Wenlan ;
Koeck, Robin ;
Fruth, Angelika ;
Bauwens, Andreas ;
Peters, Georg ;
Karch, Helge .
LANCET INFECTIOUS DISEASES, 2011, 11 (09) :671-676
[2]  
de la Cabada Bauche Javier, 2011, Gastroenterol Hepatol (N Y), V7, P88
[3]   Loperamide plus azithromycin more effectively treats travelers' diarrhea in Mexico than azithromycin alone [J].
Ericsson, Charles D. ;
DuPont, Herbert L. ;
Okhuysen, Pablo C. ;
Jiang, Zhi-Dong ;
DuPont, Margaret W. .
JOURNAL OF TRAVEL MEDICINE, 2007, 14 (05) :312-319
[4]   Epidemic Profile of Shiga-Toxin-Producing Escherichia coli O104:H4 Outbreak in Germany [J].
Frank, Christina ;
Werber, Dirk ;
Cramer, Jakob P. ;
Askar, Mona ;
Faber, Mirko ;
an der Heiden, Matthias ;
Bernard, Helen ;
Fruth, Angelika ;
Prager, Rita ;
Spode, Anke ;
Wadl, Maria ;
Zoufaly, Alexander ;
Jordan, Sabine ;
Kemper, Markus J. ;
Follin, Per ;
Muller, Luise ;
King, Lisa A. ;
Rosner, Bettina ;
Buchholz, Udo ;
Stark, Klaus ;
Krause, Gerard .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (19) :1771-1780
[5]   Travelers' diarrhea [J].
Hill, David R. ;
Beeching, Nick J. .
CURRENT OPINION IN INFECTIOUS DISEASES, 2010, 23 (05) :481-487
[6]   A review of an emerging enteric pathogen:: enteroaggregative Escherichia coli [J].
Huang, David B. ;
Mohanty, Alakananda ;
DuPont, Herbert L. ;
Okhuysen, Pablo C. ;
Chiang, Tom .
JOURNAL OF MEDICAL MICROBIOLOGY, 2006, 55 (10) :1303-1311
[7]  
Huang David B, 2004, Semin Pediatr Infect Dis, V15, P266, DOI 10.1053/j.spid.2004.07.008
[8]   Toxin gene expression by shiga toxin-producing Escherichia coli:: the role of antibiotics and the bacterial SOS response [J].
Kimmitt, PT ;
Harwood, CR ;
Barer, MR .
EMERGING INFECTIOUS DISEASES, 2000, 6 (05) :458-465
[9]   Eculizumab in Severe Shiga-Toxin-Associated HUS [J].
Lapeyraque, Anne-Laure ;
Malina, Michal ;
Fremeaux-Bacchi, Veronique ;
Boppel, Tobias ;
Kirschfink, Michael ;
Oualha, Mehdi ;
Proulx, Francois ;
Clermont, Marie-Jose ;
Le Deist, Francoise ;
Niaudet, Patrick ;
Schaefer, Franz .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (26) :2561-2563
[10]   Different Classes of Antibiotics Differentially Influence Shiga Toxin Production [J].
McGannon, Colleen Marie ;
Fuller, Cynthia Ann ;
Weiss, Alison Ann .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (09) :3790-3798